Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

42.51

+0.94

(+2.26%)

At close: 04:00PM EDT

43.00

+0.49

(+1.15%)

After hours:

07:55PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	41.57
Open	42.65
Bid	40.17 x 800
Ask	43.88 x 1000
Day's Range	39.73 - 43.83
52 Week Range	27.77 - 138.52
Volume	2,415,741
Avg. Volume	1,358,724

Market Cap	2.987B
Beta (5Y Monthly)	1.60
PE Ratio (TTM)	N/A
EPS (TTM)	-3.59
Earnings Date	Aug 08, 2022 - Aug 12, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	89.55

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BEAM

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Beam Therapeutics Inc.
Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Rating
Fair Value
Economic Moat
10 days agoMorningstar

All

Simply Wall St.
How Much Of Beam Therapeutics Inc. (NASDAQ:BEAM) Do Institutions Own?
A look at the shareholders of Beam Therapeutics Inc. ( NASDAQ:BEAM ) can tell us which group is most powerful...
- What Type Of Shareholders Make Up Kingsoft Cloud Holdings Limited's (NASDAQ:KC) Share Registry?
  Simply Wall St.
- What Type Of Shareholders Own The Most Number of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares?
  Simply Wall St.
Zacks
TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar?
TELA Bio, Inc. (TELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TipRanks
Which EV Charging Stocks Are the Best Bets? One Analyst Suggests 2 Names to Consider
The Biden administration is pushing hard to promote electric vehicles (EVs). From a $7.5 billion provision in the ‘Build Back Better’ bill to political pressure on automakers to commit to increased production with the goal of converting 40% of car sales to EVs by the end of this decade, it’s clear that under Biden, the government has the will to enforce a major shift in the automotive industry. The Biden administration has also prioritized the production of EV battery systems, to the tune of $3.